NASDAQ:BEAM
Beam Therapeutics Inc.
Beam Therapeutics Inc.'s revenue grew 120.0% in fiscal 2025 to $139.7M while operating margin rose to −274.6%. Free cash flow was −$360.0M, −257.7% of revenue, and the diluted share count rose 20.2%.Summary generated from Beam Therapeutics Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$139.7M
Revenue growth+120.0%
Revenue, 5-yr CAGR+466.3%
Gross marginn/a
Operating margin−274.6%
Net margin−57.2%
ROICn/a
Return on equity−8.1%
Debt / equityn/a
Free cash flow−$360.0M
FCF margin−257.7%
Share count change+20.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 52 | 61 | 378 | 64 | 140 |
| Operating income | −392 | −338 | −176 | −416 | −384 |
| Net income | −371 | −289 | −133 | −377 | −80 |
| Free cash flow | −113 | −26 | −183 | −356 | −360 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 25, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KResults of a shareholder vote
Jun 8, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - DEF 14AProxy statement
Apr 17, 2026